

1 **Associations between cord serum antibodies against**
2 **phosphorylcholine and bacterial infections in neonates: a**
3 **prospective cohort study in singletons and twins**

4
5 **Ruoqing Chen^{1,2,a}, Yeqi Zheng^{1,a}, Weiri Tan¹, Feng Wu¹, Hui Liang³, Xi Chen³,**
6 **Youmei Chen³, Xian Liu³, Fang Fang², Quanfu Zhang³, Rui Zhang^{3,b}, Xu Chen^{3,b}**

7
8 ¹School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, China;

9 ²Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden;

10 ³Baoan Women's and Children's Hospital, Shenzhen University, Shenzhen, China.

11 ^aR. C. and Y. Z. contributed equally to this work as co-first authors.

12 ^bR. Z. and X. C. contributed equally to this work as co-corresponding authors.

13

14 **Correspondence:** Xu Chen, PhD (Email: chuanxuchen@outlook.com) & Rui Zhang,
15 MD (Email: zhangrui0829@163.com), Baoan Women's and Children's Hospital,
16 Shenzhen University, #56 YuLv Road, Baoan District, Shenzhen, Guangdong 518100,
17 China.

18

19

20 **Key point (24 words):** A higher level of IgM anti-PC in cord serum is associated
21 with a lower risk of bacterial infection in both singleton and twin neonates.

22

23

24 **Word limit:** 2560 words (excluding the abstract and references).

25

26

27

28

29 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

30 **Abstract (236 words)**

31 **Background.** Antibodies against phosphorylcholine (anti-PC) are reported to protect
32 against infection. However, the association between cord serum anti-PC and bacterial
33 infection in neonates is yet to be investigated. This study aimed to investigate these
34 associations among both singletons and twins.

35

36 **Methods.** A total of 1007 neonates (329 singletons and 678 twins) within the
37 hospital-based Shenzhen Baoan Birth & Twin cohort were included in this study.
38 Levels of IgM anti-PC, IgG anti-PC, as well as IgM, IgG, and IgA in cord serum were
39 measured by enzyme-linked immunosorbent assay. Diagnoses of bacterial infections
40 were identified within 0-27 days after birth. Multivariable logistic regression with
41 propensity score adjustment was performed to assess the associations between levels
42 of antibodies and neonatal bacterial infections.

43

44 **Results.** The mean (standard deviation) levels of IgM and IgG anti-PC were 46.68
45 (14.15) ng/ml and 73.68 (30.44) ng/ml, respectively. Neonatal bacterial infections
46 were diagnosed in 24 singletons (7.29%) and 48 twins (7.08%). A higher level of IgM
47 anti-PC was associated with a lower risk of neonatal bacterial infections in the
48 analyses of singletons (Odds ratio [OR]: 0.64, 95% confidence interval [CI]:
49 0.41-0.99) or discordant twin pairs (concerning bacterial infection) (OR: 0.44, 95% CI:
50 0.20-0.95). Statistically significant association was also shown for IgG among
51 singletons and the first-born twins, but not for IgG anti-PC, IgM, or IgA.

52

53 **Conclusion.** A higher cord serum level of IgM anti-PC is associated with a lower risk
54 of bacterial infections in neonates.

55

56 **Keywords:** Neonatal bacterial infection; Antibody against phosphorylcholine; Cord
57 blood; Twins; Cohort study

58

59 **BACKGROUND**

60 Infection is the primary cause of death among neonates worldwide, especially in
61 developing countries [1]. In China, the standardized neonatal mortality rate was 6.22
62 per 100,000 live births in 2019 [2]. Additionally, neonatal sepsis and other infections
63 among neonates exhibited the highest standardized years lived with disability in 2019,
64 representing a significant increase compared to 1990 (117.08 versus 15.58 per
65 100,000 live births) [2].

66

67 Phosphorylcholine (PC), a phosphorylated choline derivative, is found on oxidized
68 low-density lipoprotein in atherosclerotic lesions, deceased cells, and several
69 pathogens such as *Streptococcus pneumoniae* [3] and *Staphylococcus aureus* [4]. For
70 microorganisms, PC could be synthesized using choline from the host and serve as a
71 resource of nutrients and an osmoprotectant [5, 6]. Moreover, PC allows bacteria to
72 evade host immune responses and subsequently colonize in the upper respiratory tract
73 [7, 8]. Antibodies against PC (anti-PC) were initially recognized for their
74 anti-infective properties [9] and were later reported to be a protection marker of
75 cardiovascular disease [10], autoimmune diseases [11], as well as fetal growth and
76 premature birth [12]. However, to the best of our knowledge, few studies have
77 assessed the associations between anti-PC and bacterial infections in neonates.

78

79 In this prospective cohort study of singleton and twin neonates, we aimed to
80 investigate the associations between levels of anti-PC and other antibodies in cord
81 serum and the risk of neonatal bacterial infections. We hypothesized that anti-PC are
82 protective for neonates, i.e., a higher level of anti-PC in cord serum is associated with
83 a lower risk of bacterial infections.

84

85

86 **METHODS**

87 **Study population**

88 This study was embedded in the ongoing Shenzhen Baoan Birth & Twin (SZBBTwin)

89 cohort, which was initiated in the Baoan Women's and Children's Hospital, Shenzhen
90 University, Shenzhen, China, in May 2020. Until March 2023, 343 singletons and 722
91 twins (361 twin pairs) born through cesarean section had been recruited. Medical
92 information was collected from the hospital information system, and biological
93 samples were collected at the time of birth (including cord blood, amniotic fluid,
94 tissues of placenta and umbilical cord, as well as maternal blood). Neonates without
95 cord blood samples were excluded, resulting in 329 singletons and 678 twins in this
96 study (Figure 1). This study and SZBBTwin cohort were approved by the Ethics
97 Committee of Baoan Women's and Children's Hospital (the present study:
98 LLSC2020-03-12; SZBBTwin: LLSC2019-02-18). Informed consent was obtained
99 from the mothers before delivery.

100

101 **Measurement of antibodies**

102 The primary exposures were levels of IgM anti-PC and IgG anti-PC in cord serum. To
103 explore the specificity of the associations between anti-PC and neonatal bacterial
104 infections, the total IgM, IgG, and IgA levels were also measured. Cord blood
105 samples were collected during cesarean section, and serum was separated within six
106 hours and stored at -80°C. The five types of antibodies were measured by
107 enzyme-linked immunosorbent assay (ELISA) kits (Jianglaibio Co., Ltd., Shanghai,
108 China) (details in Supplementary Table 1). The cord serum samples underwent first
109 equilibration to room temperature, after which, 50uL of each sample were diluted into
110 250uL test samples (including 200ul diluent). A double-antibody sandwich ELISA
111 was performed according to the manufacturer's instructions: 1) 50uL of test samples
112 (penta diluted), calibrators (standard samples), and blank controls (diluent) were
113 dispensed in wells on the pre-coated plates (96 wells); the plates were then sealed and
114 incubated at 37°C for 60 minutes; 2) the contents in wells were aspirated, and 100uL
115 of Horseradish peroxidase conjugated antibody was added in each well; then the
116 plates were sealed and incubated at 37°C for 60 minutes; 3) all contents were
117 aspirated, and 350uL of 1× wash buffer was added and then removed after one
118 minute's incubation (this washing step was repeated for five times); 4) 100uL

119 Trimethylbenzene substrate was added in each well, and then incubated at 37°C for 15
120 minutes; and 5) 50uL stop solution was added in each well, and the optical density
121 (OD, absorbance at 450nm) was measured within 15 minutes (RT-6100, Rayto Life
122 and Analytical Sciences Co.,Ltd., Shenzhen, China). For each plate, the standard
123 curve was generated using linear regression, in which the concentrations and OD
124 values of calibrators (standard samples) were plotted on the X and Y axis, respectively.
125 The concentrations of antibodies in test samples were quantified using the curve
126 equation, and the actual concentrations in cord serum were calculated with dilution
127 factor (test value ×5).

128

129 **Neonatal bacterial infection**

130 Neonatal bacterial infection was defined as a diagnosis of bacterial infection within
131 0-27 days of age. Information on diagnoses was derived from medical records from
132 hospital admissions, outpatient visits, and emergency visits. Additionally, results of
133 laboratory tests, including blood culture, sputum culture, complete blood count,
134 procalcitonin, and C-reactive protein, were used to validate the presence of bacterial
135 infections. Bacterial infection was identified by one of the following criteria: positive
136 sputum culture, positive blood culture, elevated levels of infection indicators in
137 complete blood count (white blood cell count and neutrophil count),
138 procalcitonin>0.05 ng/ml, or C-reactive protein>10 mg/L. For diagnoses during
139 outpatient visits, the presence of purulent secretions observed at physical examination
140 and prescriptions of antibiotics were additionally taken into account.

141

142 **Covariates**

143 Maternal and neonatal characteristics were collected from the hospital information
144 system. These characteristics included maternal age at delivery [13], parity [14],
145 educational level [15], mode of conception [16], pre-pregnancy body mass index
146 (BMI) [17], vaginal bleeding during early pregnancy [18], diabetic diseases [19],
147 hypertensive diseases [20], infectious diseases during pregnancy [21], anemia during
148 pregnancy [22], and gestational age at delivery [21]. Characteristics of neonates

149 included sex [23] and birth weight [21].

150

151 For twin neonates, information on chorionicity and zygosity was also collected.

152 Chorionicity was determined by ultrasound examinations during the antenatal visit at

153 11-13 gestational weeks. Opposite-sex twin pairs were considered as dizygotes. For

154 the same-sex twin pairs, DNA was extracted from the cord blood using whole blood

155 genomic DNA purification kits and automatic instrument (MagaBio Plus and

156 NPA-32P, Bioer Technology Co., Ltd., Hangzhou, China). The short tandem repeat

157 genotyping (36A ID System, Microread Genetics Co., Ltd., Beijing, China) was

158 further used to identify the zygosity of same-sex twin pairs.

159

160 **Statistical analyses**

161 To address batch effects and ensure that levels of antibodies followed a normal

162 distribution for analyses, levels of all antibodies were adjusted for batch variations by

163 computing residuals based on assay kit batches, followed by rank transformation.

164 Continuous variables were described using mean and standard deviation (SD), and the

165 means of different groups were compared by the Student's t-test. Categorical variables

166 were described using frequencies and proportions, with group comparisons being

167 performed using the Chi-squared test.

168

169 Multivariable logistic regression was used to assess the associations of anti-PC and

170 other antibodies with the risk of neonatal bacterial infections. Model 1 was a crude

171 model. To increase the efficiency of confounding adjustment, we computed a

172 propensity score by modeling a linear regression, with the level of a specific antibody

173 as the dependent variable, and maternal characteristics, including age at delivery,

174 parity, educational level, mode of conception, pre-pregnancy BMI, vaginal bleeding in

175 early pregnancy, diabetic diseases, hypertensive diseases, infectious diseases during

176 pregnancy, anemia during pregnancy, and gestational age at delivery, as well as sex

177 and birth weight of the neonates as the independent variables. In the analyses for

178 singletons, Model 2 adjusted for the propensity score. For analyses of twins,

179 chronicity and zygosity were additionally considered based on Model 2 (Model 3).

180

181 To explore the potential impact of birth order on the levels of specific antibodies and
182 neonatal bacterial infection, we performed separate analyses for the first-born twins
183 and second-born twins. To control for unmeasured genetic and environmental factors
184 shared by twins, the analyses were repeated in a sub-sample of twin pairs discordant
185 for neonatal bacterial infection, i.e., discordant twin pairs, using conditional logistic
186 regression (only adjusted for sex and birth weight of the neonates, Model 4).

187

188

189 **RESULTS**

190 In this study, a total of 1007 neonates (329 singletons and 678 twins) were included.
191 Maternal and neonatal characteristics at baseline are shown in Table 1 and Table 2.
192 Neonatal bacterial infections, including pneumonia, septicemia, upper respiratory
193 tract infection, and other infections, were observed in 24 (7.29%) singleton and 48
194 (7.08%) twin neonates (Figure 1).

195

196 Compared with non-infected neonates, the infected neonates were more likely to have
197 mothers who experienced vaginal bleeding during pregnancy and to have been born at
198 a lower gestational age and through emergency cesarean section (Supplementary
199 Table 2). Among twins, neonatal bacterial infections were more likely to occur in twin
200 pregnancies of monozygotic types.

201

202 The cord serum levels of IgM anti-PC and IgG anti-PC were on average 46.68 ± 14.15
203 ng/ml and 73.68 ± 30.44 ng/ml , respectively (Table 3). The cord serum levels of
204 anti-PC were lower in the first-born twins than the second-born twins; the IgM
205 anti-PC levels were 36.99 ± 13.26 ng/ml versus 48.01 ± 11.38 ng/ml , whereas the IgG
206 anti-PC levels were 60.22 ± 23.97 ng/ml versus 88.51 ± 24.13 ng/ml . Similar difference
207 between the first- and second-born twins was also found for total IgM, IgG and IgA.
208 Cord serum levels of anti-PC and other antibodies in relation to maternal and neonatal

209 characteristics in all neonates, singletons, and twins are shown in Supplementary
210 Tables 3 and 4.

211

212 After adjustment for propensity score (Table 4), a higher IgM anti-PC level was
213 associated with a lower risk of bacterial infection in the analyses of singletons (odds
214 ratio (OR) 0.64, 95% confidence interval (CI): 0.41-0.99) or discordant twin pairs
215 (OR: 0.44, 95% CI: 0.20-0.95). A higher level of IgG was also associated with a low
216 risk of bacterial infection among singletons and the first-born twins, regardless of
217 adjustment for propensity score. However, such association was not observed among
218 the second-born twins or in the analysis of discordant twin pairs. No association was
219 shown for levels of IgG anti-PC, IgM, or IgA, with the risk of bacterial infections in
220 any groups of neonates.

221

222

223 **DISCUSSION**

224 In this hospital-based prospective cohort study of singleton and twin neonates, a
225 higher level of IgM anti-PC in cord serum was associated with a lower risk of
226 neonatal bacterial infections in the analyses of singletons or discordant twin pairs.
227 Similar results were found for IgG in singletons and the first-born twins. However, no
228 evidence was observed for associations of IgG anti-PC, IgM, and IgA with neonatal
229 bacterial infections.

230

231 We found that a higher cord serum level of IgM anti-PC, not total IgM, was associated
232 with a lower risk of neonatal bacterial infection. PC is a specific epitope on several
233 pathogens, such as *Streptococcus pyogenes* [24], *Haemophilus influenzae* [25], and
234 *Neisseria* [26]. Previous animal experiments suggest that anti-PC may protect the host
235 against pneumococcal infection [27, 28]. Moreover, the presence of anti-PC induced
236 by exposure to PC-containing bacteria underscores its protective role in inhibiting the
237 development of allergic diseases [29]. Therefore, anti-PC may be considered a
238 potential marker for the immune status of neonates.

239

240 The association between IgG anti-PC and bacterial infection was not statistically
241 significant in any groups of neonates, but total IgG showed a protective effect on
242 neonatal bacterial infection in singletons. Such pattern is similar to findings from a
243 prospective study of Brazilian twins [30], which showed a higher level of total IgG in
244 cord blood of non-infected neonates than infected neonates. Furthermore, a previous
245 study suggested that cord blood concentrations of serotype III-specific IgG surpassing
246 7 µg/ml was associated with protection against Group B Streptococci infection in
247 neonates[31], while another study revealed that the majority of neonates with IgG
248 levels below 7 µg/ml would not develop Group B Streptococci infection [32].

249

250 Interestingly, we found also an association for IgG in the first-born twins but not in
251 the second-born twins, although no difference was observed in the frequency of
252 bacterial infections between the first- and second-born twins. However, IgG level of
253 the first-born twins was lower than that of second-born twins, suggesting that the
254 first-born twins might be more vulnerable to infection. As for IgA, an Indian study
255 found that IgA concentration in umbilical cord blood might not be a reliable marker
256 for predicting neonatal bacterial infections [33], corroborating the present study.

257

258 There are several strengths in our study. First, the cord serum levels of antibodies
259 could reflect directly the initial immune status of neonates [34]. Second, the
260 incorporation of twin design could control for shared genetic and environmental
261 confounding factors between twins, enhancing the internal validity of the study. Third,
262 the use of propensity score adjustment is statistically advantageous in case of small
263 number of outcomes. Nevertheless, some limitations should also be acknowledged.
264 First, we had limited information on the pathogens of neonatal bacterial infections,
265 precluding the possibility of analyzing infections of specific bacteria. Second,
266 collecting cord blood from neonates with small gestational age is challenging, which
267 might have precluded some of the neonates from being enrolled in the SZBBTwin
268 cohort. As a result, the twins in this study might have a larger gestational age than the

269 overall twin population at the hospital who might have higher incidence of neonatal
270 bacterial infection. This, together with the inclusion of only neonates delivered via
271 cesarean section, limits the generalizability of our findings. Third, other biological
272 samples (such as peripheral venous blood) were not collected from neonates, limiting
273 the possibility of studying the dynamic profiles of immunoglobulins in relation to
274 neonatal bacterial infections.

275

276 It is worth noting that the study period of the present study included the COVID-19
277 pandemic when diverse mitigating policies were implemented in China. Coupled with
278 variations in clinical practice in obstetric and neonatal units, this might have
279 introduced additional variation to the results. The implementation of infection control
280 measures, such as enhanced hygiene protocols, visitor restrictions, and changes in
281 hospital workflows, could have influenced the healthcare environment for pregnant
282 women and neonates during this period. These alterations, in turn, might have altered
283 the immune system of neonates, potentially influencing their early life health
284 outcomes, including bacterial infections [35].

285

286 In conclusion, our study found that a higher level of IgM anti-PC in cord serum was
287 associated with a lower risk of neonatal bacterial infections among singletons and
288 twins. Additionally, higher IgG levels were associated with a lower risk of such
289 infections among singletons and the first-born twins. However, associations of IgG
290 anti-PC, IgM, and IgA with neonatal bacterial infections were not observed in either
291 singletons or twins. Further studies are required to investigate the mechanisms
292 underlying the associations. The clinical use of IgM anti-PC in preventing neonatal
293 bacterial infections is also worthy with further exploration.

294

295

296 **ACKNOWLEDGEMENTS**

297 The authors would like to thank Dr. Likuan Xiong, Dr. Bin Liu, Dr. Yuanfang Zhu,
298 and Dr. Xu Chen (former president) from Shenzhen Baoan Women's and Children's

299 Hospital for the construction of the SZBBTwin cohort.

300

301 **Author contributions**

302 Ruoqing Chen and Xu Chen conceptualized the study. Yeqi Zheng, Weiri Tan, and
303 Feng Wu collected and managed the data. Hui Liang and Xi Chen performed the
304 assays. Xian Liu, Youmei Chen, Quanfu Zhang, and Rui Zhang recruited the
305 participants and collected the samples. Yeqi Zheng performed the statistical analyses
306 and wrote the initial draft of the manuscript. Ruoqing Chen, Fang Fang, and Xu Chen
307 revised the manuscript. All authors have read and agreed to the final version of the
308 manuscript.

309

310 **Funding sources**

311 This study was funded by the 100 Talents Plan Foundation of Sun Yat-sen University
312 (R. Chen, Grant No.: 58000-12230022), the Guangdong Basic and Applied Basic
313 Research Fund (R. Chen, Grant No.: 2022A1515110417), the Science, Technology
314 and Innovation Council of Shenzhen [X. Chen, Grant No.: JCYJ20190809152801661],
315 and the National Natural Science Foundation of China (X. Chen, Grant No.:
316 82001652).

317

318 **Conflict of interest**

319 The authors declare no conflict of interest.

320

321 **Supplementary Data**

322 Supplementary tables are available online.

323

324

325

326 **REFERENCES**

- 327 1. Burstein R, Henry NJ, Collison ML, et al. Mapping 123 million neonatal, infant and child
328 deaths between 2000 and 2017. *Nature* **2019**; 574(7778): 353-358.
- 329 2. Wang H, Fan W, Yang X. Disease burden of neonatal diseases in China in 1990 and 2019: a
330 comparison analysis. *Chinese Journal of Public Health* **2023**; 39(5): 556-561.

- 331 3. Iuchi H, Ohori J, Kyutoku T, Ito K, Kurono Y. Role of phosphorylcholine in *Streptococcus*
332 *pneumoniae* and nontypeable *Haemophilus influenzae* adherence to epithelial cells. *Auris*
333 *Nasus Larynx* **2019**; 46(4): 513-519.
- 334 4. Schwiering M, Brack A, Stork R, Hellmann N. Lipid and phase specificity of α -toxin from *S.*
335 *aureus*. *Biochimica et Biophysica Acta (BBA) - Biomembranes* **2013**; 1828(8): 1962-1972.
- 336 5. Wargo MJ. Homeostasis and catabolism of choline and glycine betaine: lessons from
337 *Pseudomonas aeruginosa*. *Appl Environ Microbiol* **2013**; 79(7): 2112-2120.
- 338 6. Fitzsimmons LF, Hampel KJ, Wargo MJ. Cellular choline and glycine betaine pools impact
339 osmoprotection and phospholipase C production in *Pseudomonas aeruginosa*. *J Bacteriol* **2012**;
340 194(17): 4718-4726.
- 341 7. Kleetz J, Vasilopoulos G, Czolkoss S, Aktas M, Narberhaus F. Recombinant and endogenous
342 ways to produce methylated phospholipids in *Escherichia coli*. *Appl Microbiol Biotechnol*
343 **2021**; 105(23): 8837-8851.
- 344 8. Sohlenkamp C, López-Lara IM, Geiger O. Biosynthesis of phosphatidylcholine in bacteria.
345 *Prog Lipid Res* **2003**; 42(2): 115-162.
- 346 9. Ohori J, Jimura T, Kurono Y. Role of Phosphorylcholine-specific immunoglobulin M in acute
347 upper respiratory tract infections. *Ann Otol Rhinol Laryngol* **2019**; 128(6_suppl): 111s-116s.
- 348 10. Samal SK, Panda PK, Vikström M, et al. Antibodies against phosphorylcholine among
349 60-year-olds: clinical role and simulated interactions. *Front Cardiovasc Med* **2022**; 9: 809007.
- 350 11. Thiagarajan D, Fiskesund R, Frostegård A, et al. Immunoglobulin G1 antibodies against
351 phosphorylcholine are associated with protection in systemic lupus erythematosus and
352 atherosclerosis: potential underlying mechanisms. *ACR Open Rheumatol* **2020**; 2(6): 344-356.
- 353 12. Frostegård AG, Sjöberg BG, Frostegård J, Norman M. IgM-antibodies against
354 phosphorylcholine in mothers and normal or low birth weight term newborn infants. *PLoS*
355 *One* **2014**; 9(9): e106584.
- 356 13. Herstad L, Klungsoyr K, Skjærven R, et al. Elective cesarean section or not? Maternal age and
357 risk of adverse outcomes at term: a population-based registry study of low-risk primiparous
358 women. *BMC Pregnancy Childbirth* **2016**; 16: 230.
- 359 14. Clements T, Rice TF, Vamvakas G, et al. Update on transplacental transfer of IgG subclasses:
360 impact of maternal and fetal factors. *Front Immunol* **2020**; 11: 1920.
- 361 15. Noghanibehambari H, Salari M, Tavassoli N. Maternal human capital and infants' health
362 outcomes: evidence from minimum dropout age policies in the US. *SSM Popul Health* **2022**;
363 19: 101163.
- 364 16. Waynforth D. Effects of Conception Using assisted reproductive technologies on infant health
365 and development: an evolutionary perspective and analysis using UK Millennium cohort data.
366 *Yale J Biol Med* **2018**; 91(3): 225-235.
- 367 17. Villamor E, Norman M, Johansson S, Cnattingius S. Maternal obesity and risk of early-onset
368 neonatal bacterial sepsis: nationwide cohort and sibling-controlled studies. *Clin Infect Dis*
369 **2021**; 73(9): e2656-e2664.
- 370 18. Lucovnik M, Tul N, Verdenik I, Blickstein I. Perinatal outcomes in singleton and twin
371 pregnancies following first-trimester bleeding. *J Perinatol* **2014**; 34(9): 673-676.
- 372 19. Wang BB, Xue M. Early neonatal complications in pregnant women with gestational diabetes
373 mellitus and the effects of glycemic control on neonatal infection. *World J Diabetes* **2023**;
374 14(9): 1393-1402.

- 375 20. Luo F, Liu F, Guo Y, et al. Single-cell profiling reveals immune disturbances landscape and
376 HLA-F-mediated immune tolerance at the maternal-fetal interface in preeclampsia. *Front*
377 *Immunol* **2023**; 14: 1234577.
- 378 21. Guo L, Han W, Su Y, et al. Perinatal risk factors for neonatal early-onset sepsis: a
379 meta-analysis of observational studies. *J Matern Fetal Neonatal Med* **2023**; 36(2): 2259049.
- 380 22. Frost JN, Tan TK, Abbas M, et al. Hepcidin-mediated hypoferremia disrupts immune
381 responses to vaccination and infection. *Med* **2021**; 2(2): 164-179.e12.
- 382 23. Klein SL, Flanagan KL. Sex differences in immune responses. *Nat Rev Immunol* **2016**; 16(10):
383 626-638.
- 384 24. Iuchi H, Ohori J, Matsuzaki H, Tokushige T, Toge S, Yamashita M. Impact of
385 phosphorylcholine expression on the adherence and invasion of *Streptococcus pyogenes* to
386 epithelial cells. *Microorganisms* **2022**; 10(3): 527.
- 387 25. Clark SE, Snow J, Li J, Zola TA, Weiser JN. Phosphorylcholine allows for evasion of
388 bactericidal antibody by *Haemophilus influenzae*. *PLoS pathogens* **2012**; 8(3): e1002521.
- 389 26. Serino L, Virji M. Genetic and functional analysis of the phosphorylcholine moiety of
390 commensal *Neisseria lipopolysaccharide*. *Molecular microbiology* **2002**; 43(2): 437-448.
- 391 27. McDaniel LS, Benjamin WH, Jr., Forman C, Briles DE. Blood clearance by
392 anti-phosphocholine antibodies as a mechanism of protection in experimental pneumococcal
393 bacteremia. *J Immunol* **1984**; 133(6): 3308-3312.
- 394 28. Mold C, Rodic-Polic B, Du Clos TW. Protection from *Streptococcus pneumoniae* infection by
395 C-reactive protein and natural antibody requires complement but not Fc gamma receptors. *J*
396 *Immunol* **2002**; 168(12): 6375-6381.
- 397 29. Patel PS, Kearney JF. Neonatal exposure to pneumococcal phosphorylcholine modulates the
398 development of house dust mite allergy during adult life. *J Immunol* **2015**; 194(12):
399 5838-5850.
- 400 30. Yoshida RAM, Palmeira P, Carneiro-Sampaio M, Brizot ML, Carvalho WB, Krebs VLJ.
401 Neonatal infection and passive acquisition of serum total IgG and reactive with
402 "Streptococcus" B, anti-LPS of "Klebsiella spp" and "Pseudomonas spp" antibodies in twins.
403 *Rev Assoc Med Bras (1992)* **2020**; 66(6): 824-829.
- 404 31. Lin FY, Weisman LE, Azimi PH, et al. Level of maternal IgG anti-group B streptococcus type
405 III antibody correlated with protection of neonates against early-onset disease caused by this
406 pathogen. *J Infect Dis* **2004**; 190(5): 928-934.
- 407 32. Fujieda M, Aoyagi Y, Matsubara K, et al. L-ficolin and capsular polysaccharide-specific IgG
408 in cord serum contribute synergistically to opsonophagocytic killing of serotype III and V
409 group B streptococci. *Infect Immun* **2012**; 80(6): 2053-2060.
- 410 33. Jain A, Jain K, Jhurani D, et al. Umbilical cord blood IgA levels and bacterial profile in
411 preterm neonates born with maternal risk factors for early-onset neonatal sepsis. *Indian*
412 *journal of pediatrics* **2023**: 1-7.
- 413 34. Baloh CH, Venturi GM, Fischer BM, et al. Biomarkers detected in cord blood predict vaccine
414 responses in young infants. *Front Immunol* **2023**; 14: 1152538.
- 415 35. Adhikari EH, Spong CY. COVID-19 vaccination in pregnant and lactating women. *JAMA*
416 **2021**; 325(11): 1039-1040.
- 417

418 **FIGURE LEGENDS**

419

420 **Figure 1.** Flow chart of inclusion and exclusion of the study population.

421

Table 1. Maternal characteristics at baseline of the study

Characteristics	All	Singletons	Twins	<i>P</i>^a
Mothers, N (%)^b	682 (100.00)	329 (48.24)	353 (51.76)	
Age at delivery (years), mean (SD)	32.41 (4.41)	32.99 (4.42)	31.86 (4.33)	0.001 ^c
Age at delivery (years), N (%)				
19-24	22 (3.23)	9 (2.74)	13 (3.68)	0.001 ^d
25-29	181 (26.54)	67 (20.36)	114 (32.29)	
30-34	300 (43.99)	149 (45.29)	151 (42.78)	
≥35	179 (26.25)	104 (31.61)	75 (21.25)	
Parity, N (%)				
1	333 (48.83)	98 (29.79)	235 (66.57)	<0.001 ^d
2	281 (41.20)	189 (57.45)	92 (26.06)	
3	61 (8.94)	37 (11.25)	24 (6.80)	
≥4	7 (1.03)	5 (1.52)	2 (0.57)	
Educational level, N (%)				
Junior high school or below	82 (12.02)	36 (10.94)	46 (13.03)	0.580 ^d
Senior high school or vocational school	112 (16.42)	60 (18.24)	52 (14.73)	
University or above	476 (69.79)	227 (69.00)	249 (70.54)	
Missing	12 (1.76)	6 (1.82)	6 (1.70)	
Mode of conception, N (%)				
Naturally conceived	473 (69.35)	299 (90.88)	174 (49.29)	<0.001 ^d
IVF-ET	209 (30.65)	30 (9.12)	179 (50.71)	
Pre-pregnancy BMI, mean (SD)	21.73 (3.18)	21.95 (3.45)	21.52 (2.90)	0.080 ^c
Pre-pregnancy BMI, N (%)				
<18.5	86 (12.61)	41 (12.46)	45 (12.75)	0.469 ^d
18.5-23.9	463 (67.89)	217 (65.96)	246 (69.69)	
24.0-27.9	105 (15.40)	54 (16.41)	51 (14.45)	
≥28.0	28 (4.11)	17 (5.17)	11 (3.12)	
Vaginal bleeding during early pregnancy, N (%)				
No	549 (80.50)	257 (78.12)	292 (82.72)	0.129 ^d
Yes	133 (19.50)	72 (21.88)	61 (17.28)	
Diabetic disease, N (%)				
No	494 (72.43)	245 (74.47)	249 (70.54)	0.346 ^d
Pregestational diabetes mellitus	1 (0.15)	0 (0.00)	1 (0.28)	
Gestational diabetes	187 (27.42)	84 (25.53)	103 (29.18)	
Hypertensive disease, N (%)				
No	539 (79.03)	261 (79.33)	278 (78.75)	0.090 ^d
Gestational hypertension	56 (8.21)	33 (10.03)	23 (6.52)	
Eclampsia and preeclampsia	87 (12.76)	35 (10.64)	52 (14.73)	
Infection diseases during pregnancy, N (%)				
No	505 (74.05)	238 (72.34)	267 (75.64)	0.326 ^d
Yes	177 (25.95)	91 (27.66)	86 (24.36)	
Anemia during pregnancy, N (%)				
No	326 (47.80)	143 (43.47)	183 (51.84)	0.029 ^d
Yes	356 (52.20)	186 (56.53)	170 (48.16)	
Gestational age at delivery (days), mean (SD)	263.35 (9.97)	270.15 (8.27)	257.02 (6.73)	<0.001 ^c

Gestational age at delivery(weeks), N (%)^e

<34	5 (0.73)	0 (0.00)	5 (1.42)	<0.001 ^d
34-36	162 (23.75)	20 (6.08)		
34	0	0	19 (5.38)	
35	0	0	26 (7.37)	
36	0	0	97 (27.48)	
≥37	0	0	206 (58.36)	
37-38	366 (53.67)	160 (48.63)	0	
39-40	140 (20.53)	140 (42.55)	0	
≥41	9 (1.32)	9 (2.74)	0	

Mode of delivery

Elective cesarean section	673 (98.68)	325 (98.78)	348 (98.58)	0.819 ^d
Emergency cesarean section	9 (1.32)	4 (1.22)	5 (1.42)	

SD: Standard deviation; IVF-ET: In vitro fertilization and embryo transfer; BMI: Body mass index.

^a *P* value represents the level of significance in comparing the baseline maternal characteristics between singletons and twins.

^b Number and row percentage.

^c Student's t-test.

^d Chi-squared test.

^e Gestational age at delivery was classified as <34, 34-36, 37-38, 39-40, ≥41 weeks for all and singleton neonates, and as <34, 34, 35, 36, ≥37 weeks for twin neonates.

Table 2. Neonatal characteristics at baseline of the study

Characteristics	All	Singletons	Twins	<i>P</i> ^a
Neonates, N (%)^b	1007 (100.00)	329 (32.67)	678 (67.33)	
First-born neonates				
Sex, N (%)				
Female	469 (46.57)	149 (45.29)	156 (45.48)	0.569 ^c
Male	538 (53.43)	180 (54.71)	187 (54.52)	
Birth weight (grams), mean (SD)	2735.60 (516.45)	3228.32 (452.64)	2502.01 (350.74)	<0.001 ^d
Birth weight (grams), N (%)^e				
≤2000	61 (6.06)	1 (0.30)	31 (9.04)	<0.001 ^c
2000-2499	243 (24.13)	12 (3.65)	115 (33.53)	
2500-2999	419 (41.61)	80 (24.32)	172 (50.15)	
≥3000			25 (7.29)	
3000-3499	191 (18.97)	144 (43.77)		
3500-3999	78 (7.75)	77 (23.40)		
≥4000	15 (1.49)	15 (4.56)		
Second-born neonates				
Sex, N (%)				
Female	-	-	164 (48.96)	
Male	-	-	171 (51.04)	
Birth weight (grams), mean (SD)	-	-	2490.87 (347.78)	
Birth weight (grams), N (%)				
≤2000	-	-	29 (8.66)	
2000-2499	-	-	116 (34.63)	
2500-2999	-	-	167 (49.85)	
≥3000	-	-	23 (6.87)	
Chorionicity, N (%)				
Monochorionic monoamniotic	-	-	3 (0.91)	
Monochorionic diamniotic	-	-	97 (29.48)	
Dichorionic diamniotic	-	-	253 (76.90)	
Zygoty, N (%)				
Monozygote	-	-	243 (35.84)	
Opposite-sex dizygote	-	-	413 (60.91)	
Same-sex dizygote	-	-	22 (3.24)	

SD: Standard deviation.

^a *P* value represents the level of significance in comparing the baseline neonatal characteristics between singletons and twins.

^b Number and row percentage.

^c Chi-squared test.

^d Student's t-test.

^e Birth weight was classified as ≤2000, 2000-2499, 2500-2999, 3000-3499, 3500-3999, ≥4000 grams for all and singleton neonates; and as ≤2000, 2000-2499, 2500-2999, ≥3000 grams for twin neonates.

Table 3. Levels of anti-PC and other antibodies in cord serum among the study population

Participants	IgM anti-PC (ng/ml)	IgG anti-PC (ng/ml)	IgM (µg/ml)	IgG (µg/ml)	IgA (µg/ml)
All neonates					
Total (N=1007)	46.68 (14.15)	73.68 (30.44)	682.51 (303.15)	11903.58 (4402.83)	1831.12 (488.45)
Female (N=469)	46.57 (14.19)	75.24 (29.67)	684.12 (298.85)	11723.43 (4269.60)	1844.14 (498.66)
Male (N=538)	46.78 (14.13)	72.32 (31.06)	681.11 (307.11)	12060.62 (4513.86)	1819.78 (479.54)
<i>P</i> ^a	0.788	0.134	0.839	0.223	0.495
Singletons					
Total (N=329)	55.44 (11.03)	72.61 (35.14)	697.54 (368.68)	12236.43 (6096.09)	1768.84 (584.97)
Female (N=149)	54.31 (10.93)	73.78 (33.16)	681.41 (365.25)	11412.68 (5912.28)	1787.87 (599.09)
Male (N=180)	56.37 (11.05)	71.65 (36.76)	710.89 (371.99)	12918.31 (6177.58)	1753.09 (574.23)
<i>P</i> ^a	0.091	0.522	0.643	0.021	0.309
Twins					
Total (N=678)	42.43 (13.53)	74.20 (27.89)	675.22 (265.59)	11742.06 (3274.24)	1861.35 (431.20)
Female (N=320)	42.96 (14.10)	75.92 (27.93)	685.38 (262.93)	11868.12 (3234.31)	1870.35 (442.87)
Male (N=358)	41.96 (13.01)	72.66 (27.80)	666.13 (267.99)	11629.38 (3309.98)	1853.30 (420.96)
<i>P</i> ^a	0.400	0.111	0.387	0.291	0.551
First-born twins					
Total (N=343)	36.99 (13.26)	60.22 (23.97)	551.71 (232.52)	10140.77 (2662.70)	1656.49 (338.45)
Female (N=156)	36.62 (13.65)	62.63 (25.54)	552.39 (226.10)	10351.45 (2676.86)	1655.85 (347.83)
Male (N=187)	37.30 (12.95)	58.21 (22.45)	551.15 (238.34)	9965.02 (2645.14)	1657.02 (331.37)
<i>P</i> ^a	0.474	0.064	0.979	0.180	0.933
Second-born twins					
Total (N=335)	48.01 (11.38)	88.51 (24.13)	801.67 (236.47)	13381.59 (3023.43)	2071.10 (415.16)
Female (N=164)	49.00 (11.69)	88.56 (24.01)	811.89 (231.63)	13310.81 (3059.86)	2074.38 (427.65)
Male (N=171)	47.06 (11.04)	88.46 (24.31)	791.87 (241.29)	13449.48 (2995.48)	2067.95 (404.06)
<i>P</i> ^a	0.107	0.942	0.452	0.737	0.862
<i>P</i> ^b	0.723	0.086	0.175	0.093	0.250
<i>P</i> ^c	<0.001	<0.001	<0.001	<0.001	<0.001

Levels were presented as mean (standard deviation).

Anti-PC: Antibodies against phosphorylcholine; IgM: Immunoglobulin M; IgG: Immunoglobulin G; IgA: Immunoglobulin A.

^a Student's t-test was used to compare the mean levels of antibodies between female and male neonates.

^b Student's t-test was used to compare the mean levels of antibodies between twins and singletons.

^c Student's t-test was used to compare the mean levels of antibodies between the first-born and the second-born twins.

Table 4. Associations of anti-PC and other antibodies with risk of neonatal bacterial infection among the study population

Participants	IgM anti-PC (ng/ml)	IgG anti-PC (ng/ml)	IgM (µg/ml)	IgG (µg/ml)	IgA (µg/ml)
Singletons (N=329)					
Non-infected, mean (SD)	55.73 (11.07)	72.65 (34.80)	706.48 (369.22)	12491.51 (6020.97)	1759.62 (575.56)
Infected, mean (SD)	51.77 (9.99)	72.10 (40.03)	583.89 (349.37)	8994.76 (6243.48)	1886.03 (697.07)
Model 1 ^a , OR (95%CI)	0.67 (0.45-1.01)	1.00 (0.64-1.58)	0.82 (0.56-1.20)	0.61 (0.40-0.92)	1.01 (0.62-1.65)
Model 2 ^b , OR (95%CI)	0.64 (0.41-0.99)	1.00 (0.62-1.63)	0.82 (0.55-1.24)	0.62 (0.39-0.96)	0.98 (0.59-1.62)
Twins (N=678)					
Non-infected, mean (SD)	42.66 (13.56)	73.62 (28.04)	674.79 (265.88)	11776.07 (3275.54)	1856.04 (432.25)
Infected, mean (SD)	39.43 (12.87)	81.76 (24.81)	680.88 (264.55)	11295.71 (3258.17)	1931.05 (415.26)
Model 1 ^a , OR (95%CI)	1.05 (0.79-1.40)	1.15 (0.90-1.47)	0.93 (0.69-1.24)	0.76 (0.57-1.01)	1.00 (0.78-1.28)
Model 3 ^c , OR (95%CI)	1.00 (0.75-1.33)	1.17 (0.90-1.53)	0.90 (0.67-1.20)	0.78 (0.57-1.05)	0.98 (0.77-1.26)
First-born twins (N=343)					
Non-infected, mean (SD)	37.33 (13.51)	59.48 (24.32)	553.56 (233.38)	10199.73 (2683.38)	1650.39 (337.81)
Infected, mean (SD)	32.43 (8.27)	70.04 (16.19)	527.17 (224.04)	9357.09 (2276.07)	1737.56 (343.78)
Model 1 ^a , OR (95%CI)	0.96 (0.62-1.47)	1.31 (0.83-2.07)	0.74 (0.45-1.20)	0.58 (0.35-0.94)	1.03 (0.62-1.70)
Model 3 ^c , OR (95%CI)	1.00 (0.63-1.57)	1.27 (0.78-2.06)	0.75 (0.45-1.26)	0.58 (0.34-0.98)	1.03 (0.61-1.73)
Second-born twins (N=335)					
Non-infected, mean (SD)	48.13 (11.27)	88.12 (23.93)	799.13 (238.60)	13392.96 (3033.78)	2066.97 (417.00)
Infected, mean (SD)	46.43 (12.97)	93.49 (26.62)	834.58 (208.60)	13234.33 (2944.34)	2124.54 (395.04)
Model 1 ^a , OR (95%CI)	1.21 (0.73-2.01)	1.07 (0.65-1.77)	1.09 (0.68-1.75)	0.81 (0.51-1.30)	0.97 (0.62-1.51)
Model 3 ^c , OR (95%CI)	1.03 (0.60-1.78)	1.28 (0.75-2.18)	0.99 (0.60-1.64)	0.82 (0.50-1.34)	0.87 (0.55-1.39)
Discordant twins (N=56)					
Non-infected, mean (SD)	47.05 (10.74)	81.85 (30.70)	669.64 (290.16)	12153.50 (3405.26)	1944.06 (447.85)
Infected, mean (SD)	39.89 (14.60)	82.63 (27.17)	716.12 (270.70)	11136.43 (3096.45)	1970.14 (394.77)
Model 1 ^a , OR (95%CI)	0.57 (0.31-1.03)	1.04 (0.66-1.63)	1.13 (0.73-1.77)	0.78 (0.48-1.26)	1.07 (0.62-1.84)
Model 4 ^d , OR (95%CI)	0.44 (0.20-0.95)	0.93 (0.55-1.56)	1.10 (0.67-1.79)	0.69 (0.39-1.22)	0.86 (0.45-1.65)

Anti-PC: Antibody against phosphorylcholine; IgM: Immunoglobulin M; IgG: Immunoglobulin G; IgA: Immunoglobulin A; SD: Standard deviation; OR: Odds ratio; CI: Confidence interval.

^a Mode 1 is a crude model.

^b Model 2 adjusted for propensity scores, which were computed from a linear regression model with maternal age at delivery, parity, educational level, mode of conception, prepregnancy body mass index, vaginal bleeding during early pregnancy, diabetic diseases, hypertensive diseases, infection diseases during pregnancy, anemia during pregnancy, gestational age at delivery, and sex and birth weight of the neonates as independent variables and specific antibody as dependent variable.

^c Model 3 adjusted for propensity scores, which were computed from a linear regression model with variables adjusted in Model 2 plus chronicity and zygosity as independent variables and specific antibody as dependent variable.

^d Model 4 adjusted for sex and birth weight of the neonates.

Neonates from the Shenzhen Baoan Birth & Twin (SZBBTwin) cohort

Singletons born from 2020-05-05 to 2023-03-09

Twins born from 2020-05-06 to 2023-02-21

Singletons

N=343

Twins

N=722
(361 pairs)

N=14

Exclusion

N=44

Without cord blood samples

Singletons

N=329

Study population

Twins

N=678*

Antibodies in cord serum

IgM anti-PC, IgG anti-PC, IgM, IgG, IgA



N (%)

305 92.71

24 7.29

8 2.43

3 0.91

5 1.52

8 2.43

Bacterial infections during 0-27 days

No

Yes

Neonatal pneumonia

Neonatal septicemia

Upper respiratory tract infection

Other infections

N (%)

630 92.92

48 7.08

29 4.28

4 0.59

1 0.15

14 2.06

* 325 pairs (including 28 pairs of discordant twins) and 28 un-paired twins